Fig. 1: MARV binding and neutralizing antibodies in MVD survivors. | Nature Communications

Fig. 1: MARV binding and neutralizing antibodies in MVD survivors.

From: Longitudinal proteome-wide antibody profiling in Marburg virus survivors identifies wing domain immunogen for vaccine design

Fig. 1

a Overview of cohort with longitudinal convalescent samples collected approximately every six months from 10 MVD survivors and 10 matched uninfected local cohort from the 2012 Uganda outbreak. Comprehensive antibody profiling of each plasma sample was performed via Marburg virion neutralizing antibodies in PRNT, MARV-proteome wide IgM, IgG, IgA epitope repertoire by GFPDL, recombinant MARV protein binding antibody kinetics using surface plasmon resonance and Fc-receptor interactions in Luminex assay. b Neutralizing titer (PRNT50) against wild-type MARV Ci67 are shown for the 10 MVD survivors (in colors) and 10 uninfected controls (in black did not show any detectable virus neutralization). A positive control human serum sample demonstrated neutralization activity against MARV with a PRNT50 titer of 1:160 and is depicted as dashed line. Source data are provided as a Source Data file.

Back to article page